Literature DB >> 8134399

Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition.

B E Johansson1, E D Kilbourne.   

Abstract

Based on the absence of serologic cross-reactivity, the neuraminidases (NAs) of influenza A viruses are divided into antigenically discrete subtypes, analogous to the hemagglutinin (HA) major antigens with which they share the virion surface. An innovative approach to influenza vaccination takes advantage of the infection-permissive nature of immunization with NA as the minor surface antigen. However, evidence that HA dominates immune response when HA and NA are presented together in the intact virion prompted investigation of possible competing effects during immunization of NA subtype mixtures ultimately required for human vaccination. Immunization of BALB/c mice with purified N1- and N2-subtype NAs demonstrated no antigenic competition in primary or secondary response. However, when homotypic or heterotypic infection followed immunization, cross-reactive antibodies between N1 and N2 were found and "reverse antigen competition" occurred with initial NA priming suppressing response to HA following infection with virus containing homologous NA. These studies of antigen mixtures have implications for the use of combined and chimeric vaccines for diseases other than influenza.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8134399      PMCID: PMC43370          DOI: 10.1073/pnas.91.6.2358

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene.

Authors:  D A Buonagurio; S Nakada; J D Parvin; M Krystal; P Palese; W M Fitch
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

2.  Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins.

Authors:  B E Johansson; T M Moran; E D Kilbourne
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Evolution of influenza virus genes.

Authors:  H Hayashida; H Toh; R Kikuno; T Miyata
Journal:  Mol Biol Evol       Date:  1985-07       Impact factor: 16.240

4.  Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience.

Authors:  B E Johansson; T M Moran; C A Bona; S W Popple; E D Kilbourne
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

5.  Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans.

Authors:  E D Kilbourne
Journal:  J Infect Dis       Date:  1976-10       Impact factor: 5.226

6.  The importance of antineuraminidase antibodies in resistance to influenza A and immunologic memory for their synthesis.

Authors:  A N Naikhin; I M Tsaritsina; E V Oleinikova; L G Syrodoeva; N L Korchanova; G M Denisov
Journal:  J Hyg (Lond)       Date:  1983-08

7.  Antiviral activity of antiserum specific for an influenza virus neuraminidase.

Authors:  E D Kilbourne; W G Laver; J L Schulman; R G Webster
Journal:  J Virol       Date:  1968-04       Impact factor: 5.103

8.  Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection.

Authors:  K R Beutner; T Chow; E Rubi; J Strussenberg; J Clement; P L Ogra
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

9.  Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

Authors:  M P Schutze; C Leclerc; M Jolivet; F Audibert; L Chedid
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

10.  Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans.

Authors:  P L Ogra; T Chow; K R Beutner; E Rubi; J Strussenberg; S DeMello; C Rizzone
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

View more
  17 in total

1.  Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay.

Authors:  Christophe Dercamp; Violette Sanchez; Julie Barrier; Emanuelle Trannoy; Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs.

Authors:  I V Alymova; S Kodihalli; E A Govorkova; B Fanget; C Gerdil; R G Webster
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 3.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 4.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

Review 5.  Developments of subunit and VLP vaccines against influenza A virus.

Authors:  Ma-ping Deng; Zhi-hong Hu; Hua-lin Wang; Fei Deng
Journal:  Virol Sin       Date:  2012-06-09       Impact factor: 4.327

6.  Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Authors:  Zach Menne; Vasilis C Pliasas; Richard W Compans; Sheniqua Glover; Constantinos S Kyriakis; Ioanna Skountzou
Journal:  Virology       Date:  2021-08-05       Impact factor: 3.513

7.  Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.

Authors:  Kyoko Shinya; Yutaka Fujii; Hiroshi Ito; Toshihiro Ito; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Computational docking of antibody-antigen complexes, opportunities and pitfalls illustrated by influenza hemagglutinin.

Authors:  Mattia Pedotti; Luca Simonelli; Elsa Livoti; Luca Varani
Journal:  Int J Mol Sci       Date:  2011-01-05       Impact factor: 5.923

9.  Prospects for universal influenza virus vaccine.

Authors:  Walter Gerhard; Krystyna Mozdzanowska; Darya Zharikova
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

10.  A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.

Authors:  Glendie Marcelin; Rebecca DuBois; Adam Rubrum; Charles J Russell; Janet E McElhaney; Richard J Webby
Journal:  PLoS One       Date:  2011-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.